Carcinoid Tumor |
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma |
|
|
| No Longer Available | 3b | | US | Talimogene Laherparepvec | Amgen | Unresected Stage IIIb to IVM1c Melanoma | | | | |
SANO, NCT02705651: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment |
|
|
| Not yet recruiting | 3 | 180 | NA | Somatostatin-Analog | Medical University of Vienna | Pancreatic Neuroendocrine Tumors in MEN1 | 10/23 | 10/24 | | |
PROTECT, NCT03172299: Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma |
|
|
| Recruiting | 3 | 56 | Europe | Aflibercept Injection, False injection | Centre Hospitalier Universitaire de Nice | Ocular Melanoma | 06/25 | 12/26 | | |
NCT02755675 / 2015-005642-59: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung |
|
|
| Recruiting | 2 | 120 | Europe | 68Ga-NOTA-AE105 PET/CT | Rigshospitalet, Denmark | Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung | 04/23 | 10/23 | | |
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT02498756: Cytokine-induced Killer Study for Patients With Stage II Melanoma |
|
|
| Not yet recruiting | 2 | 300 | RoW | Cytokine-induced killer cells, Ipilimumab | The First People's Hospital of Changzhou | Melanoma | 08/38 | 08/40 | | |
NCT02870244: Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes |
|
|
| Recruiting | 1b | 18 | US | Escalating Doses | Loyola University, National Cancer Institute (NCI) | Melanoma | 09/28 | 09/28 | | |
| No Longer Available | N/A | | US | CP-675,206 | Pfizer | Advanced Unresectable Melanoma | | | | |
NCT01005537: Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US | aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Melanoma (Skin) | 10/10 | | | |
NCT00495066: Compassionate Use Trial for Unresectable Melanoma With Ipilimumab |
|
|
| No Longer Available | N/A | | RoW | Ipilimumab | Bristol-Myers Squibb | Melanoma | | | | |
|
|
|
|
|
|
|
|
|
NCT01338389: Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy |
|
|
| Completed | N/A | 21 | Europe | CITICOLINE, PLACEBO | Centre Hospitalier Universitaire de Nice, DENSMORE pharmaceuticals | Uveal Melanoma | 06/17 | 06/17 | | |
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
|
|
| No Longer Available | N/A | | US | Melphalan, Percutaneous Hepatic Perfusion | Delcath Systems Inc. | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | | | | |
NCT02358018: 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial |
|
|
| No Longer Available | N/A | | US | 68Ga-DOTATOC PET/CT Scan | Memorial Sloan Kettering Cancer Center | Neuroendocrine Tumors | | | | |
CheckMate 218, NCT02186249: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US, Canada | Nivolumab, Ipilimumab | Bristol-Myers Squibb | Malignant Melanoma | | | | |
|
NCT02416232 / 2014-005149-40: Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma |
|
|
| No Longer Available | N/A | | Europe | Trametinib, Dabrafenib | GlaxoSmithKline | Melanoma | | | | |
NCT01980732: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors |
|
|
| No Longer Available | N/A | | US | 68Ga-DOTA TATE | Andrei Iagaru | Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors | | | | |
NCT02083484: Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) |
|
|
| No Longer Available | N/A | | NA | Pembrolizumab | Merck Sharp & Dohme LLC | Melanoma | | | | |
|
|
|
| No Longer Available | N/A | | US, Canada, RoW | Nivolumab | Bristol-Myers Squibb | Stage III (Unresectable) or Stage IV Advanced Melanoma | 05/18 | 05/18 | | |
NCT02375464: Gallium-68 DOTATOC for Management of Neuroendocrine Tumors |
|
|
| No Longer Available | N/A | | US | Gallium-68 DOTATOC, Gallium-68 (DOTA0-Phe1-Tyr3)octreotide | Northwell Health | Neuroendocrine Tumors | 12/18 | 12/19 | | |
| Active, not recruiting | N/A | 296 | Europe | | European Organisation for Research and Treatment of Cancer - EORTC | Cutaneous Melanoma | 12/23 | 12/31 | | |
NCT00872391: Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma |
|
|
| Recruiting | N/A | 155 | Europe | Hypofractionated linear accelerator radiotherapy | Medical University of Vienna | Uveal Melanoma | 03/24 | | | |
| Recruiting | N/A | 10000 | Europe | clinical biological data collection on melanoma | Institut Claudius Regaud | Melanoma | 01/26 | 06/26 | | |
TRIM, NCT03116412: A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma |
|
|
| Recruiting | N/A | 1300 | Europe | CT or PET scans | Uppsala University | Malignant Melanoma | 12/28 | 12/28 | | |
NCT01438658: Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma |
|
|
| Recruiting | N/A | 250 | RoW | | Hadassah Medical Organization | Uveal Melanoma | 12/40 | 12/40 | | |